2020
Survival in Patients With Brain Metastases: Summary Report on the Updated Diagnosis-Specific Graded Prognostic Assessment and Definition of the Eligibility Quotient.
Sperduto PW, Mesko S, Li J, Cagney D, Aizer A, Lin NU, Nesbit E, Kruser TJ, Chan J, Braunstein S, Lee J, Kirkpatrick JP, Breen W, Brown PD, Shi D, Shih HA, Soliman H, Sahgal A, Shanley R, Sperduto WA, Lou E, Everett A, Boggs DH, Masucci L, Roberge D, Remick J, Plichta K, Buatti JM, Jain S, Gaspar LE, Wu CC, Wang TJC, Bryant J, Chuong M, An Y, Chiang V, Nakano T, Aoyama H, Mehta MP. Survival in Patients With Brain Metastases: Summary Report on the Updated Diagnosis-Specific Graded Prognostic Assessment and Definition of the Eligibility Quotient. Journal Of Clinical Oncology 2020, 38: 3773-3784. PMID: 32931399, PMCID: PMC7655019, DOI: 10.1200/jco.20.01255.Peer-Reviewed Original ResearchConceptsGraded Prognostic AssessmentDiagnosis-Specific Graded Prognostic AssessmentBrain metastasesPrognostic factorsClinical trialsPrognostic assessmentLarge contemporary cohortSignificant prognostic factorsEnrollment of patientsNew prognostic factorsMulti-institutional databaseMedian survivalMultivariable analysisContemporary cohortWorse prognosisCell lungIndividualize treatmentTreatment choicePoor survivalRenal cancerPatientsPromising treatmentExpansion of eligibilityMetastasisPrimary site
2019
Role of Gamma Knife Radiosurgery in Small Cell Lung Cancer: A Multi-Institutional Retrospective Study of the International Radiosurgery Research Foundation (IRRF)
Cifarelli CP, Vargo JA, Fang W, Liscak R, Guseynova K, Warnick RE, Lee CC, Yang HC, Borghei-Razavi H, Maiti T, Siddiqui ZA, Yuan JC, Grills IS, Mathieu D, Touchette CJ, Cordeiro D, Chiang V, Hess J, Tien CJ, Faramand A, Kano H, Barnett GH, Sheehan JP, Lunsford LD. Role of Gamma Knife Radiosurgery in Small Cell Lung Cancer: A Multi-Institutional Retrospective Study of the International Radiosurgery Research Foundation (IRRF). Neurosurgery 2019, 87: 664-671. PMID: 31599324, PMCID: PMC7780439, DOI: 10.1093/neuros/nyz428.Peer-Reviewed Original ResearchConceptsSmall cell lung cancerWhole-brain irradiationSCLC brain metastasesInternational Radiosurgery Research FoundationDistant brain failureBrain metastasesOverall survivalStereotactic radiosurgerySCLC patientsBrain failureLung cancerPrior whole-brain irradiationMulti-institutional retrospective reviewKaplan-Meier survival analysisCox proportional hazards modelLocal failureProphylactic cranial irradiationInstitutional retrospective studyMedian marginal doseOngoing prospective trialsCell lung cancerGamma knife radiosurgeryInstitutional review boardValue of radiosurgeryBinary logistic regressionInitial SRS for Patients With 5 to 15 Brain Metastases: Results of a Multi-Institutional Experience
Hughes RT, Masters AH, McTyre ER, Farris MK, Chung C, Page BR, Kleinberg LR, Hepel J, Contessa JN, Chiang V, Ruiz J, Watabe K, Su J, Fiveash JB, Braunstein S, Chao S, Attia A, Ayala-Peacock DN, Chan MD. Initial SRS for Patients With 5 to 15 Brain Metastases: Results of a Multi-Institutional Experience. International Journal Of Radiation Oncology • Biology • Physics 2019, 104: 1091-1098. PMID: 30959122, DOI: 10.1016/j.ijrobp.2019.03.052.Peer-Reviewed Original ResearchMeSH KeywordsAgedBrain NeoplasmsCranial IrradiationFemaleHumansKaplan-Meier EstimateMaleMiddle AgedProportional Hazards ModelsRadiosurgerySalvage TherapySurvival AnalysisTreatment OutcomeConceptsDistant brain failureInitial stereotactic radiosurgerySalvage whole brain radiation therapyWhole-brain radiation therapySalvage stereotactic radiosurgeryBrain metastasesBrain radiation therapyOverall survivalStereotactic radiosurgeryBM groupCumulative incidenceRadiation therapyNumber of BMTwo-year cumulative incidenceMultivariable Cox proportional hazardsBrain metastasis velocityMedian overall survivalOutcomes of patientsKaplan-Meier methodLog-rank testMulti-institutional experienceRisk regression modelingCox proportional hazardsMultivariable analysisNew metastases
2017
Improving the Prognostic Value of Disease-Specific Graded Prognostic Assessment Model for Renal Cell Carcinoma by Incorporation of Cumulative Intracranial Tumor Volume
Ali MA, Hirshman BR, Wilson B, Schupper AJ, Joshi R, Proudfoot JA, Goetsch SJ, Alksne JF, Ott K, Aiyama H, Nagano O, Carter BS, Chiang V, Serizawa T, Yamamoto M, Chen CC. Improving the Prognostic Value of Disease-Specific Graded Prognostic Assessment Model for Renal Cell Carcinoma by Incorporation of Cumulative Intracranial Tumor Volume. World Neurosurgery 2017, 108: 151-156. PMID: 28754641, PMCID: PMC5705321, DOI: 10.1016/j.wneu.2017.07.109.Peer-Reviewed Original ResearchConceptsCumulative intracranial tumor volumeNumber of BMKarnofsky performance scoreNet reclassification indexIntracranial tumor volumePrognostic assessment modelBrain metastasesPrognostic valueStereotactic radiosurgeryLogistic regression modelsTumor volumeMultivariable Cox proportional hazards modelsRenal cell carcinoma patientsUnivariable logistic regression modelsMultivariable logistic regression modelCox proportional hazards modelNew brain metastasesRCC brain metastasesCell carcinoma patientsImportant prognostic variablesRenal cell carcinomaProportional hazards modelRCC patient survivalBM patientsDS-GPAThe Prognostic Value of BRAF, C-KIT, and NRAS Mutations in Melanoma Patients With Brain Metastases
Sperduto PW, Jiang W, Brown PD, Braunstein S, Sneed P, Wattson DA, Shih HA, Bangdiwala A, Shanley R, Lockney NA, Beal K, Lou E, Amatruda T, Sperduto WA, Kirkpatrick JP, Yeh N, Gaspar LE, Molitoris JK, Masucci L, Roberge D, Yu J, Chiang V, Mehta M. The Prognostic Value of BRAF, C-KIT, and NRAS Mutations in Melanoma Patients With Brain Metastases. International Journal Of Radiation Oncology • Biology • Physics 2017, 98: 1069-1077. PMID: 28721890, PMCID: PMC6925531, DOI: 10.1016/j.ijrobp.2017.03.030.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic AgentsBrain NeoplasmsFemaleGenes, rasHumansImmunotherapyLinear ModelsMaleMelanomaMiddle AgedMolecular Targeted TherapyMutationPrognosisProportional Hazards ModelsProto-Oncogene Proteins B-rafProto-Oncogene Proteins c-kitRetrospective StudiesStatistics, NonparametricTime FactorsConceptsBRAF-negative patientsBRAF-positive patientsBrain metastasesMedian survivalC-kit mutationsMelanoma patientsPrimary diagnosisWhole-brain radiation therapyOverall median survivalMulti-institutional databaseGene mutation statusOverall survivalInitial treatmentMedian timeTreatment patternsClinical parametersBRAF statusPrognostic valueNRAS mutationsRadiation therapyPatientsMutation statusMetastasisC-kitMEK inhibitors
2015
Characterization of PD-L1 Expression and Associated T-cell Infiltrates in Metastatic Melanoma Samples from Variable Anatomic Sites
Kluger HM, Zito CR, Barr ML, Baine MK, Chiang VL, Sznol M, Rimm DL, Chen L, Jilaveanu LB. Characterization of PD-L1 Expression and Associated T-cell Infiltrates in Metastatic Melanoma Samples from Variable Anatomic Sites. Clinical Cancer Research 2015, 21: 3052-3060. PMID: 25788491, PMCID: PMC4490112, DOI: 10.1158/1078-0432.ccr-14-3073.Peer-Reviewed Original ResearchConceptsPD-L1 expressionT-cell contentPD-1/PD-L1 inhibitorsHigher T-cell contentT-cell infiltratesPD-L1 inhibitorsAnatomic sitesBrain metastasesMetastatic melanomaTissue microarrayHigh PD-L1 expressionLess PD-L1 expressionLow PD-L1 expressionTumor PD-L1 expressionHigher TIL contentImproved overall survivalT cell infiltrationLess T cellsMetastatic melanoma samplesExtracerebral metastasesCerebral metastasesOverall survivalDermal metastasesImproved survivalPD-L1
2013
The effect of tumor subtype on the time from primary diagnosis to development of brain metastases and survival in patients with breast cancer
Sperduto PW, Kased N, Roberge D, Chao ST, Shanley R, Luo X, Sneed PK, Suh J, Weil RJ, Jensen AW, Brown PD, Shih HA, Kirkpatrick J, Gaspar LE, Fiveash JB, Chiang V, Knisely JP, Sperduto CM, Lin N, Mehta M. The effect of tumor subtype on the time from primary diagnosis to development of brain metastases and survival in patients with breast cancer. Journal Of Neuro-Oncology 2013, 112: 467-472. PMID: 23462853, DOI: 10.1007/s11060-013-1083-9.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBrain NeoplasmsBreast NeoplasmsFemaleHumansMaleMiddle AgedPrognosisProportional Hazards ModelsReceptor, ErbB-2Receptors, EstrogenReceptors, ProgesteroneTimeConceptsNumber of BMBrain metastasesGraded Prognostic AssessmentPrimary diagnosisPrognostic factorsTumor subtypesMedian survivalBreast cancerDiagnosis-Specific Graded Prognostic AssessmentDevelopment of BMMulti-institutional retrospective databaseImportant prognostic factorIndependent prognostic factorBreast cancer patientsER/PRBreast cancer subtypesBreast-GPAProspective studyCancer patientsLuminal ALuminal BRetrospective databaseHER2 subtypeBrain MRIPrognostic assessment
2012
Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival.
Knisely JP, Yu JB, Flanigan J, Sznol M, Kluger HM, Chiang VL. Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival. Journal Of Neurosurgery 2012, 117: 227-33. PMID: 22702482, PMCID: PMC6098938, DOI: 10.3171/2012.5.jns111929.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntibodies, MonoclonalAntineoplastic AgentsBrain NeoplasmsCombined Modality TherapyCompassionate Use TrialsDisease-Free SurvivalFemaleHumansIpilimumabMaleMelanomaMiddle AgedNeoplasm StagingPrognosisProportional Hazards ModelsRadiosurgeryRetreatmentRetrospective StudiesConceptsMelanoma brain metastasesBrain metastasesPerformance statusMedian survivalDiagnosis-Specific Graded Prognostic Assessment (DS-GPA) scoreInstitutional review board-approved chart reviewSurvival rateGraded Prognostic Assessment scoreBrain metastasis diagnosisPrognostic assessment scoreSurvival of patientsNumber of metastasesDS-GPA scoreRadiation therapy usePrimary disease locationBrain oligometastasesIpilimumab groupIpilimumab useSalvage WBRTChart reviewOverall survivalPatient ageSystemic therapyTherapy useClinical variables
2011
Effect of Tumor Subtype on Survival and the Graded Prognostic Assessment for Patients With Breast Cancer and Brain Metastases
Sperduto PW, Kased N, Roberge D, Xu Z, Shanley R, Luo X, Sneed PK, Chao ST, Weil RJ, Suh J, Bhatt A, Jensen AW, Brown PD, Shih HA, Kirkpatrick J, Gaspar LE, Fiveash JB, Chiang V, Knisely JP, Sperduto CM, Lin N, Mehta M. Effect of Tumor Subtype on Survival and the Graded Prognostic Assessment for Patients With Breast Cancer and Brain Metastases. International Journal Of Radiation Oncology • Biology • Physics 2011, 82: 2111-2117. PMID: 21497451, PMCID: PMC3172400, DOI: 10.1016/j.ijrobp.2011.02.027.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsAgedAged, 80 and overBrain NeoplasmsBreast NeoplasmsBreast Neoplasms, MaleCohort StudiesFemaleHumansKarnofsky Performance StatusMaleMiddle AgedMultivariate AnalysisPrognosisProportional Hazards ModelsReceptor, ErbB-2Receptors, EstrogenReceptors, ProgesteroneRetrospective StudiesConceptsGraded Prognostic AssessmentER/PRKarnofsky performance statusMultivariate Cox regressionBrain metastasesBreast-GPATumor subtypesPrognostic factorsCox regressionBreast cancerPrognostic assessmentDiagnosis-Specific Graded Prognostic AssessmentMulti-institutional retrospective databaseER/PR statusHER2-positive patientsHER2-negative patientsSignificant prognostic factorsSubgroup of patientsBreast cancer patientsClinical decision makingLog-rank statisticsKPS 60Performance statusPR statusCancer patients